The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
974
May 10, 1996
View Complete Issue         Table of Contents 2019 
Chloroxazone Hepatotoxicity
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Chloroxazone Hepatotoxicity
May 10, 1996 (Issue: 974)
The US Food and Drug Administration (FDA) recently approved a stronger warning about hepatotoxicity in the labeling for chlorzoxazone, a centrally-acting skeletal muscle relaxant.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Chloroxazone Hepatotoxicity
Article code: 974b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.